SANA - Sana Biotechnology Debt to Book Capitalization Ratio

Corporate company logo of Sana Biotechnology, Inc. (SANA)

The operational foundation of Sana Biotechnology (SANA) remains stable due to the humanitarian status of biotechnologies and the protection of rights in the US. The share price history on the GURU.Markets platform, where the indicator stands at 0.46, reflects complex certification processes and prolonged R&D expenditures. The business relies on developing methods to mask cells from the immune system, which creates a significant technological moat and attracts strategic partners.

SANA Sana Biotechnology: Debt to Book Capitalization Ratio in the range 07/04/2022 - 10/28/2026

Summary analytical data breakdowns for Sana Biotechnology Inc (SANA)

- price and consensus price forecast:
Stock Price Sana Biotechnology|SANA - Consensus Target
- market capitalization data:
Market Value Sana Corp|SANA - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Sana Biotechnology|SANA - Company Book Value|Market Value to Book Value Ratio sana.com|SANA - Company Assets
- debt and liquidity data:
Total Debt to Capital Sana Biotechnology|SANA - Long-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio Sana Bio|SANA - Company Cumulative Debt|Debt to Book Value Sana Corp
Analysis of all company metrics:SANA, Sana Biotechnology
Finished products of Sana Corp

Developing innovative cell therapy methods requires colossal expenditures; therefore, correlating debt levels with balance sheet capital allows for an assessment of the funding stability for R&D projects at Sana Biotechnology (SANA). This ratio measures the proportion of borrowed funds within the equity structure, helping investors determine the level of financial leverage and the risk of liquidity loss during the implementation of a long-term expansion strategy in the gene medicine market.

Competitors of Sana Biotechnology

Legend Biotech - Debts to Book Capitalization|autolus.com - Debt to Book Value|ALLO (Allogene) - Debt to Book Capitalization Ratio|RNAC: Debts to Book Value|cellectis.com (CLLS) - Debt to Book Capitalization Ratio|CRBU (Caribou Biosciences, Inc) - Debt to Book Capitalization Ratio|Debt to Book Capitalization Ratio TIL (Instil Bio, Inc.)|Debts to Book Value Genenta|IPSC: Debts to Book Capitalization|Debt to Net Assets jaspertherapeutics.com JSPR|SNTI: Debt to Book Value|ADAP - Debts to Book Value|Debt to Book Value CERo Therapeutics Holdings Inc. (CERO)|TCRT - Debt to Net Assets Ratio|ACHL (achillestx.com) - Debts to Book Capitalization|CARGO Therapeutics Inc. (CRGX) - Debt to Book Value|Debts to Book Capitalization PSTX (Poseida)|Debts to Book Value TSVT|Debt to Book Capitalization Ratio Gracell Biotechnologies (GRCL)